Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | PRKCB | P05771 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCH | P24723 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.42 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11572401 | 1.00 | USP2 (0.50) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL2420872 | 1.00 | USP2 (0.50) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL11042865 | 1.00 | USP2 (0.50) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL2839409 | 1.00 | USP2 (0.50) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL17629258 | 1.00 | USP2 (0.50) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL9697472 | 0.91 | LPAR1 (0.40) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL8976908 | 0.90 | USP2 (0.48) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL11199731 | 0.89 | USP2 (0.42) | USP2LPAR1LPAR3LPAR2HTT | |
| SCHEMBL20573193 | 0.89 | LPAR1 (0.50) | LPAR1LPAR3 | |
| SCHEMBL994359 | 0.89 | LPAR1 (0.50) | LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169309-B1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS AG (CH) | 2023-05-10 | — | — | EP | claimed |
| WO-2010030730-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | claimed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| WO-2009129387-A2 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| EP-3986866-B1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | PREC NANOSYSTEMS ULC (CA) | 2023-12-20 | — | — | EP | disclosed |
| EP-4223285-A2 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | Novartis AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-3169309-B1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS AG (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20220396548-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2022-12-15 | — | — | US | disclosed |
| EP-3986866-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | Precision Nanosystems Inc (CA) | 2022-04-27 | — | — | EP | disclosed |
| US-11066667-B2 | Organic compositions to treat APOC3-related diseases | Arrowhead Pharmaceuticals, Inc. (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2020252589-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | Precision Nanosystems Inc. (CA) | 2020-12-24 | — | — | WO | disclosed |
| EP-3736334-A1 | RNAI COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | Arrowhead Pharmaceuticals, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10342761-B2 | Method of encapsulating a nucleic acid in a lipid nanoparticle host | NOVARTIS AG (CH) | 2019-07-09 | — | — | US | disclosed |
| US-10240153-B2 | Organic compositions to treat APOC3-related diseases | Arrowhead Pharmaceuticals, Inc. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170137814-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-05-18 | — | — | US | disclosed |
| EP-1007003-A1 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | Genzyme Corporation (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998013026-A1 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-04-02 | — | — | WO | disclosed |
| EP-0795015-A1 | PLASMIDS SUITABLE FOR IL-2 EXPRESSION | VICAL INCORPORATED (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996017063-A1 | PLASMIDS SUITABLE FOR IL-2 EXPRESSION | VICAL INCORPORATED (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396548-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | RNASEH1, NSUN3, SLC67A1 | USP2 4282/4885LPAR1 189/4885LPAR3 370/4885 |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | POLN, POLRMT, RNGTT | USP2 2226/4885LPAR1 184/4885LPAR3 405/4885 |
| US-10342761-B2 | Method of encapsulating a nucleic acid in a lipid nanoparticle host | POLN, POLRMT, RNGTT | USP2 2226/4885LPAR1 184/4885LPAR3 405/4885 |
| US-20170137814-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | APOL1, APOB, LDLR | USP2 802/4885LPAR1 1937/4885LPAR3 689/4885 |
| US-10240153-B2 | Organic compositions to treat APOC3-related diseases | APOL1, APOB, LDLR | USP2 802/4885LPAR1 1937/4885LPAR3 689/4885 |
| US-11066667-B2 | Organic compositions to treat APOC3-related diseases | APOL1, APOB, LDLR | USP2 802/4885LPAR1 1937/4885LPAR3 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.